Videos

Assessing Treatment Decisions for Myasthenia Gravis: George Small, MD

The neurologist at the Corinne Goldsmith Dickinson Center for MS offered a brief overview of his experience at the 2022 IFN conference held in New York City on September 23-24. [WATCH TIME: 4 minutes]

George Small, MD

October 25th 2022

Treatment Adherence in Sleep Disorders

The adult neurologist at Allegheny Health Network provided insight on the steps taken to ensure a patient with myasthenia gravis is on an effective and safe therapy. [WATCH TIME: 7 minutes]

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

Selecting Specific DORAs for Insomnia

Drs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson examine setting treatment expectations with patients and treatment adherence for sleep disorders.

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

Medical Crossfire on the Paradigm Shifts in Migraine Therapy: Jessica Ailani, MD

Ashgan A. Elshinawy, DO, shares her approach to treatment selection of DORAs and switching therapies for the management of sleep disorders.

Jessica Ailani, MD

Current State of Treating, Managing Myasthenia Gravis: George Small, MD

The director of the MedStar Georgetown University Hospital Headache Center tells her experience in a medical crossfire as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]

George Small, MD

The Benefits of Cross-Specialty Interaction at IFN 2022: Jessica Ailani, MD

The adult neurologist at Allegheny Health Network provided insight on the current state of care for myasthenia gravis and strides the community has made in recent decades. [WATCH TIME: 7 minutes]

Jessica Ailani, MD

October 23rd 2022

Positive Interim Report on Fosgonimeton, Lower ASPECTS Scores Impact Efficacy of EVT, FDA Extends Review of Tofersen

The director of the MedStar Georgetown University Hospital Headache Center shares her experience as the migraine cochair at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 5 minutes]

NeurologyLive® Staff

October 22nd 2022

Phase 3 Studies With Daridorexant for Insomnia Management

Neurology News Network for the week ending October 22, 2022. [WATCH TIME: 4 minutes]

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

FDA-Approved Therapies for the Management of Sleep Disorders

Nathaniel F. Watson, MD, highlights the use of daridorexant for treating patients with insomnia as seen from phase 3 trials and data presented at the World Sleep 2022 meeting and managing adverse events.

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

Impact of NMOSD on Women’s Health

Drs Ashgan A. Elshinawy, C. Michael Gibson, and Nathaniel F. Watson discuss FDA-approved medications currently used for the treatment of sleep disorders and insomnia, and comment on the difference between DORAs.

Michael Yeaman, PhD;Mirla Avila, MD;Michael Levy, MD, PhD;Mitzi Williams, MD

Current FDA-Approved Therapies for NMOSD Management

Experts in neurology review the occurrence and severity of infections in women and special patient populations with NMOSD and share their thoughts on the use of vaccines to prevent infections.

Michael Yeaman, PhD;Mirla Avila, MD;Michael Levy, MD, PhD;Mitzi Williams, MD

Monoclonal Antibodies for Alzheimer Disease and Lecanemab’s Potential: Richard Isaacson, MD

Michael Levy, MD, PhD, leads a discussion on the safety and efficacy of FDA-approved therapies for the management of NMOSD.

Richard S. Trosh, MD

Differences Between Fenebrutinib and Other BTK Inhibitors: Stuart Silverman, MD

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience during the Medical Crossfire session on the Alheimer pipeline that he took part in at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 7 minutes]

Stuart Silverman, MD

Focusing on the Future of Neurology at IFN 2022: Richard Isaacson, MD

The neurologist at Allegheny Health Network’s Neuroscience Institute provided insight on the mechanism of action of fenebrutinib and how it differs from other BTK inhibitors currently in development. [WATCH TIME: 3 minutes]

Richard Isaacson, MD

October 20th 2022

Sleep Disorders: Sleep and Wakefulness Pathways

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine provides commentary about his time at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 4 minutes]

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

Treatment Selection for Sleep Disorders

Nathaniel F. Watson, MD, reviews the pathways involved in sleep and wakefulness cycles as it relates to sleep disorders.

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

Exponential Growth of Research, Biomarkers in Alzheimer Disease: Thomas Wisniewski, MD

Dr Ashgan A. Elshinawy and C. Michael Gibson considers safety and efficacy factors when approaching treatment selection for sleep disorders and insomnia.

Thomas Wisniewski, MD

IFN 2022 Recap With the Dementia Chair: Richard Isaacson, MD

The director of NYU Langone’s Alzheimer’s Disease Research Center discussed noticeable advancements within the field of Alzheimer disease in recent years and how they contribute to gaining a better understanding of the disease. [WATCH TIME: 5 minutes]

Richard S. Trosh, MD

Understanding the Utility of Specific Antibody Testing in Peripheral Neuropathies: Benjamin Claytor, MD

The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine shares his experience at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 3 minutes]

Benjamin Claytor, MD

October 18th 2022

Role of Patient Communication in Sleep Disorder Management

The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

October 17th 2022

Approaching Diagnosis and Treatment of Sleep Disorders and Co-occurring Health Conditions

Ashgan A. Elshinawy, DO, comments on engaging patients in conversations around managing sleep disorders with co-occurring health conditions.

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

October 17th 2022

Amylyx’s New Treatment for the ALS Patient Community: Lawrence Steinman, MD

Experts in sleep medicine stress the importance of early diagnosis of sleep disorders and how they approach treatment in their clinics.

Lawrence Steinman, MD

October 17th 2022

Newborn Screening for Earlier Diagnosis of Duchenne Muscular Dystrophy: Emma Ciafaloni, MD

The Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University discusses what Amylyx’s FDA approved therapy means for the patient community and future research that may be performed regarding the dosage of the treatment. [WATCH TIME: 5 minutes]

Emma Ciafaloni, MD

October 16th 2022

Phase 3 LIGHTHOUSE Study Initiated, Trend Toward ASMs With Lower Teratogenic Risk, Rituximab Effects on NMOSD, MOGAD

The professor of Neurology and Pediatrics at University of Rochester Medical Center speaks spoke on the evolving treatments for Duchenne muscular dystrophy and the possibility of earlier diagnosis through newborn screening. [WATCH TIME: 4 minutes]

NeurologyLive® Staff

October 15th 2022

Screening for Sleep Disorders

Neurology News Network for the week ending October 15, 2022. [WATCH TIME: 3 minutes]

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

October 14th 2022

Complications of Sleep Disorders and Impact on Quality of Life

Dr Nathaniel F. Watson reviews screening patients for sleep disorders and referral to sleep specialists.

C. Michael Gibson, MD;Nathaniel F. Watson, MD;Ashgan Elshinawy, DO

October 14th 2022

Michael Yeaman, PhD;Mirla Avila, MD;Michael Levy, MD, PhD;Mitzi Williams, MD

Nathaniel F. Watson, MD; Ashgan A. Elshinawy, DO; and C. Michael Gibson, MD, examine complications patients encounter with sleep disorders, including for insomnia, and the impact on their quality of life.

Unmet Needs in NMOSD

October 14th 2022